An Introduction to Blueberry Therapeutics Company Overview - - PowerPoint PPT Presentation

An Introduction to Blueberry Therapeutics

David Cook Chief Scientific Officer

Blueberry Therapeutics Modern Drug Discovery and Development

Company Overview

• Founded November 2011 through private investment and grant funding
• An experienced, entrepreneurial core team with over 60 years experience in large

and small pharma and Biotech

• Operates semi-virtually with a range of trusted experts and contract partners
• Exploiting a safe, easy to use nanotechnology drug delivery platform to develop

new medicines in a range of disease indications

• Infection and inflammation
• Small and large molecule approaches
• Initial focus on the exploitation of a safe nanopolymer based drug delivery platform

in over the counter (OTC) medicines

• Look for opportunities to collaborate with academic partners to drive forward our

R&D projects and exploit our underlying technology platform

• Intellectual Property: 5 patents and 6 exclusive licenses to patented technology

Blueberry Therapeutics Modern Drug Discovery and Development

Peptide therapeutics

Current Portfolio 2015

CTA/IND AMR BB5000

Small molecule

Acne Medicine BB2312 IBD BB0109 Atopic Dermatitis BB2702

Small Molecule

Onychomycosis BB0305 Tinea pedis BB2603

Topical Biologic

Launch

Preclinical Clinical

Peptide therapeutic Peptide therapeutic

MARKET

Risk Profile

Acute Wounds BB1601

Device

Rapid to market

Over the counter Prescription

Exploiting our differentiating nanopolymer delivery platform in a range of over the counter healthcare products to marketing authorisation to rapidly generate revenue, benefit our shareholders and invest in long term projects

L M L L H H H

Blueberry Therapeutics Modern Drug Discovery and Development

Drug delivery platform

Nanocin™: A safe nanopolymer-based drug delivery system

• A non-lipid polymer with with over 30 years safe clinical use in human health
• Nanocin™ rapidly assembles into nanoparticles – packaging the cargo drug for enhanced delivery

Blueberry is exploiting the unique properties of Nanocin™ to develop a range of topical treatments for infectious and inflammatory disease

Blueberry Therapeutics Modern Drug Discovery and Development

Tackling Bacterial Antibiotic Resistance

• A new approaches to the treatment of multidrug

resistant infection

• A platform approach based on nanotech formulated

peptide aptamers which target directly the mechanisms

• f bacterial resistance restoring sensitivity to standard

antibiotics- RESISTANCE BREAKERS

• Used in combination with standard antibiotic treatments

– Treat MRSA with penicillin! – Potential for a long-term sustained response to AMR

Preclinical proof-of-concept studies

50 100 150 200 250 300

MIC [Oxacillin] ug/ml

• +
• +

+ +

Aptamer 1 Control Aptamer 2 Control MSSA

• MRSA

Scaffold 1 Scaffold 2

+

• +

+ + +

• +

+ + +

• +

+ +

Nanocin Aptamer Restoration of antibiotic sensitivity in clinical isolates of MRSA by protein aptamers blocking the resistance mechanism

Blueberry Therapeutics Modern Drug Discovery and Development

Blueberry collaborators

We are always keen to develop collaborations to help us drive forward our research and exploit this exciting new nanotechnoloy

Blueberry Therapeutics

Manchester University Newcastle University Liverpool University Leeds University Public Health England RVC SME UCL Pharma Sheffield University

Thank you

Contact: David Cook david.cook@blueberrytherapeutics.com